Want to see SE:CANTA full AI Analyst Report?

Cantargia AB (CANTA) Price & Analysis

3 Followers

CANTA Stock Chart & Stats

kr4.07

-kr0.02(-1.25%)

At close: Mar 06 4:00 PM EST

kr4.07

-kr0.02(-1.25%)

Day’s Range― - ―

52-Week Rangekr1.40 - kr6.59

Previous CloseN/A

Volume611.88K

Average Volume (3M)1.19M

Market Cap

kr429.68M

Enterprise Valuekr311.57

Total Cash (Recent Filing)kr221.96M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)2.1

Beta0.89

Next Earnings

Nov 25, 2026

EPS Estimate

-0.16

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.68

Shares Outstanding281,944,980

10 Day Avg. Volume1,026,475

30 Day Avg. Volume1,191,268

Financial Highlights & Ratios

PEG Ratio-0.04

Price to Book (P/B)3.91

Price to Sales (P/S)3.28

P/FCF Ratio6.94

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

kr12.00

Price Target Upside194.84% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-0.77

Revenue Forecast (FY)kr1.05M

Bulls Say, Bears Say

Bulls Say

Recent Profitability And Cash GenerationThe latest period shows a substantial profitability and cash-generation inflection, with free cash flow closely matching net income. If this performance persists, it can fund development internally, reduce reliance on external capital, and support continued investment across the pipeline.

Debt-free Balance SheetA debt-free balance sheet lowers fixed financial obligations and refinancing exposure while preserving flexibility for clinical development and partnerships. Positive equity and recent profitability provide a stronger buffer against operating volatility than a similarly early-stage company carrying significant leverage.

Two-program IL1RAP PipelineThe IL1RAP-focused platform supports development across both oncology and inflammatory or autoimmune diseases, giving Cantargia more than one potential application for its core research approach. Progress in either area could broaden the company’s partnering and commercialization opportunities.

Bears Say

Unproven Revenue DurabilityThe sharp contrast between current earnings and the prior years indicates that revenue and profitability have not yet demonstrated a stable, repeatable pattern. Modest recent growth further limits confidence that the latest financial base will persist through the next development and reporting cycles.

Milestone-driven Earnings VolatilityDependence on milestone or other one-time items can make reported revenue, earnings, and cash flow uneven across periods. That volatility complicates planning and reduces the visibility of internally generated funding, particularly when development spending remains necessary to advance clinical programs.

Clinical-stage Financing DependenceBecause the core assets remain in clinical development and product-sales revenue depends on future approval, ongoing operations are exposed to financing and partnering outcomes. This can constrain strategic flexibility and create funding pressure if development needs continue before recurring commercial income begins.

Cantargia AB News

Cantargia Preclinical Data Back Nadunolimab–RAS Inhibitor Combo in Aggressive Pancreatic Cancer

Cantargia AB ( ($SE:CANTA) ) just unveiled an update. Cantargia AB has reported new preclinical data presented at...

2d ago

Cantargia Ramps Up Investor Outreach with Series of September Conferences

Cantargia AB ( ($SE:CANTA) ) has shared an announcement. Cantargia AB will engage with the investment community at...

1M ago

Cantargia Maintains Buy Rating as Strategic Focus and Upcoming Nadunolimab Catalysts Offset Cut in Price Target to SEK12

Cantargia AB, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sara Nik from...

1M ago

Cantargia details pipeline and financials in H1 2026 interim report

Cantargia AB ( ($SE:CANTA) ) has shared an update. Cantargia AB has released its interim report for January...

1M ago

7V3 Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Cantargia AB (7V3) is scheduled to report 2nd quarter earnings on 08/19/2026, before the market opens. Regarding Q2...

2M ago

Cantargia schedules Q2 2026 results release and investor conference call

Cantargia AB ( ($SE:CANTA) ) has issued an announcement. Cantargia will publish its interim report for January to...

2M ago

Cantargia Expands Share Capital After Rights Issue Completion

Cantargia AB ( ($SE:CANTA) ) has provided an update. Cantargia AB has expanded its share capital following the...

2M ago

Cantargia: Nadunolimab’s Complementary Role in PDAC Supports Maintained Buy Rating and Reaffirmed $14 Target

In a report released today, Sara Nik from H.C. Wainwright reiterated a Buy rating on Cantargia AB, with...

3M ago

Cantargia Data Strengthen IL1RAP and Nadunolimab Case in Pancreatic Cancer

Cantargia AB ( ($SE:CANTA) ) has shared an update. Cantargia has reported new preclinical and clinical data in...

3M ago

Cantargia Raises SEK 75 Million in Undersubscribed Rights Issue and Grants Warrants to Fenja Capital

Cantargia AB ( ($SE:CANTA) ) has provided an announcement. Cantargia has completed a rights issue that was subscribed...

3M ago

CANTA FAQ

What was Cantargia AB’s price range in the past 12 months?

Cantargia AB lowest stock price was kr1.40 and its highest was kr6.59 in the past 12 months.

What is Cantargia AB’s market cap?

Cantargia AB’s market cap is kr429.68M.

When is Cantargia AB’s upcoming earnings report date?

Cantargia AB’s upcoming earnings report date is Nov 25, 2026 which is in 54 days.

How were Cantargia AB’s earnings last quarter?

Cantargia AB released its earnings results on Aug 19, 2026. The company reported -kr0.13 earnings per share for the quarter, beating the consensus estimate of -kr0.17 by kr0.04.

Is Cantargia AB overvalued?

According to Wall Street analysts Cantargia AB’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Cantargia AB pay dividends?

Cantargia AB does not currently pay dividends.

What is Cantargia AB’s EPS estimate?

Cantargia AB’s EPS estimate is -0.16.

How many shares outstanding does Cantargia AB have?

Cantargia AB has 281,944,980 shares outstanding.

What happened to Cantargia AB’s price movement after its last earnings report?

Cantargia AB reported an EPS of -kr0.13 in its last earnings report, beating expectations of -kr0.17. Following the earnings report the stock price went up 2.581%.

Which hedge fund is a major shareholder of Cantargia AB?

Currently, no hedge funds are holding shares in SE:CANTA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Cantargia AB

Cantargia AB (publ), a biotechnology company established in Lund, Sweden, in 2010, is dedicated to the research and development of antibody-driven therapies for severe illnesses. Its lead product, CAN04, is an antibody specifically engineered to target Interleukin-1 Receptor Accessory Protein (IL1RAP). This innovative treatment aims to identify and stimulate the immune system to destroy cancer cells, while also mitigating tumor-related inflammation fueled by the Interleukin-1 system, and is currently in Phase IIa clinical trials. The company is also advancing CAN10, another IL1RAP-specific antibody, through preclinical development for autoimmune and inflammatory conditions like systemic sclerosis and myocarditis. Additionally, Cantargia is exploring other CANxx antibodies that also interact with IL1RAP. The manufacturing and production of CAN04 are facilitated through partnerships with Patheon Biologics BV and BioWa Inc., and its clinical study is supported by Specialized Medical Services-oncology BV.

Cantargia AB (CANTA) Earnings & Revenues

Historic Earnings Reports

CANTA Stock 12 Month Forecast

Average Price Target

kr12.00

▲(194.84% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"kr0","13":"kr13","3.25":"kr3.25","6.5":"kr6.5","9.75":"kr9.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">kr12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">kr12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">kr12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.25,6.5,9.75,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.461,2.271692307692308,3.0823846153846155,3.893076923076923,4.703769230769231,5.514461538461539,6.325153846153847,7.135846153846154,7.946538461538462,8.75723076923077,9.567923076923078,10.378615384615385,11.189307692307693,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.461,2.271692307692308,3.0823846153846155,3.893076923076923,4.703769230769231,5.514461538461539,6.325153846153847,7.135846153846154,7.946538461538462,8.75723076923077,9.567923076923078,10.378615384615385,11.189307692307693,{"y":12,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.461,2.271692307692308,3.0823846153846155,3.893076923076923,4.703769230769231,5.514461538461539,6.325153846153847,7.135846153846154,7.946538461538462,8.75723076923077,9.567923076923078,10.378615384615385,11.189307692307693,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.8,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.51,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.225,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.185,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.49,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.46,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.19,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.802,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.158,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.104,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.822,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.79,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.461,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >